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Abstract
Rationale: Biomarkers associated with response to therapy in tuberculosis could have broad clinical utility. We postulated
that the frequency of Mycobacterium tuberculosis (Mtb) specific CD8+ T cells, by virtue of detecting intracellular infection,
could be a surrogate marker of response to therapy and would decrease during effective antituberculosis
treatment. Objectives: We sought to determine the relationship of Mtb specific CD4+ T cells and CD8+ T cells with
duration of antituberculosis treatment.
Materials and Methods: We performed a prospective cohort study, enrolling between June 2008 and August 2010, of HIV-
uninfected Ugandan adults (n = 50) with acid-fast bacillus smear-positive, culture confirmed pulmonary TB at the onset of
antituberculosis treatment and the Mtb specific CD4+ and CD8+ T cell responses to ESAT-6 and CFP-10 were measured by
IFN-c ELISPOT at enrollment, week 8 and 24.
Results: There was a significant difference in the Mtb specific CD8+ T response, but not the CD4+ T cell response, over 24
weeks of antituberculosis treatment (p,0.0001), with an early difference observed at 8 weeks of therapy (p = 0.023). At 24
weeks, the estimated Mtb specific CD8+ T cell response decreased by 58%. In contrast, there was no significant difference in
the Mtb specific CD4+ T cell during the treatment. The Mtb specific CD4+ T cell response, but not the CD8+ response, was
negatively impacted by the body mass index.
Conclusions: Our data provide evidence that the Mtb specific CD8+ T cell response declines with antituberculosis treatment
and could be a surrogate marker of response to therapy. Additional research is needed to determine if the Mtb specific
CD8+ T cell response can detect early treatment failure, relapse, or to predict disease progression.
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Introduction
Modern tools such as the GeneXpertH (Cepheid; Sunnyvale,
California, USA) and line probe assays allow for the rapid
identification of Mycobacterium tuberculosis (Mtb) as well as genetic
mutations associated with drug resistance in clinical specimens.
However, precise tools to ascertain among those infected, who will
progress to tuberculosis (TB) disease, or who, once disease has
developed, will fail treatment are lacking. These tools would be
useful both for individual patient care and for clinical trials. In
both cases, biomarkers that reflect bacterial burden or response to
therapy could serve in this role.
Host factors such as cytokines, chemokines, immune cells,
antibodies to Mtb, and differential gene expression profiles have all
been investigated as potential biomarkers [1,2,3]. It has been
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postulated that the frequency and phenotype of pathogen-specific
T cells could serve as a dynamic biomarker early in treatment
[4,5]. Early studies, using an assay similar to the T-SPOTH.TB
(Oxford Immunotec, Inc, Oxfordshire, UK) enzyme-linked
immunospot assay (ELISPOT), linked the frequency of Mtb
specific T cell responses with antigenic load [6]. However,
commercial interferon gamma (IFN-c) release assays (IGRAs: T-
SPOTH.TB and QuantiFERONH; Qiagen Inc., Valencia, Cali-
fornia, USA), cannot discern TB from latent TB infection (LTBI)
[7,8], two infection phenotypes that differ significantly in bacterial
burden. Thus, it is not surprising that studies examining the role of
IGRAs as a marker of TB treatment have yielded results with a
wide dynamic range [9,10,11,12,13] _ENREF_8, making the
clinical utility of IGRAs as a biomarker of response to therapy less
clear.
We postulate that the poor correlation of IGRAs with treatment
reflects the biological inability of the CD4+ T cell to discern
differences in intracellular bacterial burden. IGRAs measure IFN-
c released by peripheral blood mononuclear cells (PBMC), which
are dominated by CD4+ T cells [14]. In this regard, CD4+ T cells
recognize antigen presented in the context of ‘‘professional’’,
MHC-II expressing antigen presenting cells, which may have
sampled their antigen from either the intracellular or extracellular
milieu. Conversely, CD8+ T cells necessarily recognize antigen
derived from an intracellular environment and could serve as
sensors of bacterial burden. In this regard, human CD8+ T cells
preferentially recognize cells heavily infected with Mtb [15] and
the magnitude of the CD8 response in animal models is correlated
with bacterial load [16,17,18]. Further, young children with TB
have a robust Mtb specific CD8+ T cell response, which is absent
from the healthy matched cohort of children with extensive
household exposure [19]. Taken together, we postulated that the
number of Mtb specific CD8+ T cells, by virtue of their ability to
respond to intracellular mycobacterial antigens, could be used as a
surrogate marker of response to therapy and thus would decrease
during effective antituberculosis treatment.
To study this question, we enrolled 50 HIV-negative subjects
with AFB smear-positive pulmonary TB and measured the Mtb
specific CD4+ and CD8+ T cell responses at three time points
during antituberculosis treatment. Our data provide evidence that
the number of Mtb specific CD8+ T cells, potentially by detecting
intracellular mycobacterial antigen, and hence intracellular
infection, declines with antituberculosis treatment and may be a
surrogate marker of response to therapy. As a secondary analysis,
to explore the differences in the Mtb specific CD4+ and CD8+
responses on antituberculous treatment, we sought to determine if
baseline nutritional differences affected or altered the association
between the Mtb specific CD8+ T cell response and treatment
duration.
Some of these results have been previously reported in an oral/
poster presentation [20].
Materials and Methods
Ethics Statement and Study Oversight
The study protocol was approved by the institutional review
boards at the Joint Clinical Research Centre, Kampala, Uganda,
University Hospitals Case Medical Center, Cleveland, Ohio, USA
and U.S. Centers for Disease Control (CDC) and the Ugandan
National Council for Science and Technology. Written informed
consent was obtained from all study participants.
Study Design
A prospective cohort study to evaluate microbial and immuno-
logic surrogate markers in response to TB treatment was
undertaken jointly by the CDC TB Trials Consortium (TBTC)
and the NIAID’s Tuberculosis Research Unit (TBRU) (TBTC
Study NAA2m/DMID 08-0023) at the Uganda-Case Western
Reserve University Collaboration sites in Kampala, Uganda. The
study describing the microbial surrogate markers will be reported
separately. Our study objectives were to evaluate the Mtb specific
CD4+ and CD8+ T cell response during antituberculosis
treatment.
Participants and Procedures
Patients aged 18 to 60 years with suspected pulmonary TB
presenting to the National TB Treatment Center at Mulago
Hospital in Kampala, Uganda between June 2008 and August
2010 were evaluated. HIV-negative, sputum AFB smear-positive
patients with cavitary disease, residing within a radius of 20
kilometers from the treatment center, no history of previous TB
treatment, and a Karnofsky Performance Scale Score .50%
(requires occasional assistance, but is able to care for most personal
needs) [21], were invited to participate after providing informed
consent. In choosing sputum smear positive patients with cavitary
disease, initial TB biomarker studies usually focus on patients with
high sputum bacillary load. The rationale for this cohort selection
is as follows: (a) it increases the chance of detecting a difference in
the biomarker during treatment, and (b) sputum smear positive
patients with pulmonary TB are the most important patient
population for TB treatment trials, where TB biomarkers would
be of use. As to the representativeness of patients with cavitary TB
of all patients with TB, the proportion of patients with cavitary
disease at the time of diagnosis ranges from 40 to 87% [22,23].
Additionally, TB treatment trials have indeed shown that
treatments that work in smear positive patients with cavitary
disease generally work in patients with less severe forms of
pulmonary TB and most forms of extrapulmonary TB. At
enrollment, a medical history and physical examination were
performed including weight and height for calculation of BMI
[24]. Sputa for AFB smear grade [25], culture on solid and liquid
MGIT media, quantitative and semi quantitative culture on solid
Middlebrook media were collected at baseline (week 0) and every 2
weeks during the intensive phase of treatment (baseline, 2, 4, 6,
and 8 weeks) and monthly during the continuation phase (3–9
months). A positive AFB smear was graded from 1 to 4+.
Posteroanterior chest radiographs (CXR) were performed at
baseline and read by chest physicians at Mulago Hospital using
a standardized scoring system considering the presence and size of
cavitary lesions and the involvement of multiple lung fields to
grade the radiographic severity and extent of disease. For extent of
disease, predefined cut-offs of limited, moderate and extensive
were used to characterize the CXR with moderate reflecting J
and extensive K of thoracic area involvement. Blood was drawn
for complete blood count, serum aspartate aminotransferase, total
bilirubin, and creatinine. In addition, blood was collected at
baseline and weeks 8 and 24 for ELISPOT analysis. All patients
received an American Thoracic Society (ATS)/Infectious Diseases
Society of America (IDSA)/CDC-recommended anti-TB chemo-
therapy regimen consisting of two months of daily isoniazid,
rifampicin, ethambutol and pyrazinamide followed by four months
(or seven months if the patient’s sputum cultures were positive
after the first two months) of daily isoniazid and rifampicin with
dosages adjusted for body weight [26]. All doses were supervised
and follow up occurred every two weeks during the intensive phase
and monthly during the continuation phase. Anti-TB drugs were
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obtained from VersaPharm, Inc., Marietta, GA, USA (rifampin)
and Svizera Europe BV, Almere, the Netherlands (isoniazid,
ethambutol and pyrazinamide), and manufactured under Good
Manufacturing Practice. Patients were followed through the end of
TB treatment.
Media and reagents
Culture medium consisted of RPMI 1640 supplemented with
10% human sera, 561025 M 2 ME (Sigma-Aldrich,http://www.
sigmaaldrich.com/), and 2 mM glutamine (GIBCO BRL, http://
www.invitrogen.com/). Peptides were synthesized by Genemed
Synthesis (http://www.genemedsyn.com/). A single synthetic
peptide pool consisting of 15-mers overlapping by 11 amino
acids, representing Mtb specific proteins, CFP-10 and ESAT-6,
was synthesized. Peptides were resuspended in DMSO, and 43
peptides were combined into one pool such that each peptide in
the pool was at a concentration of 1 mg/ml. Peptide pools were
stored at 4uC.
IFN-c Enzyme Linked Immunospot (ELISPOT) assay
To measure Mtb specific CD4+ and CD8+ T cell responses,
overnight IFN-c ELISPOT assays were performed as described
previously [19,27] using a single synthetic pool consisting of 15-
mers overlapping by 11amino acids, representing Mtb specific
proteins, CFP-10 and ESAT-6. To achieve CD4 and CD8
separation and ensure quality control on the separated fractions,
CD8 and CD4/CD56 depleted cells were isolated using the
Miltenyi magnetic bead general protocol as previously described
[19]. Negative and positive controls consisted of cells cultured with
medium alone or phytohemagglutanin (PHA, 10 mg/ml; EMD
Biosciences, http://www.emdbiosciences.com/), respectively for
quality assessment. All CD4 and CD8 T cell determinations were
performed in duplicate and media (control) wells without antigen
were performed in triplicate. IFN-c producing Mtb specific T cells
were enumerated per 250,000 T cells. All assays were performed
at the Joint Clinical Research Centre in Kampala, Uganda.
Statistical Analysis
The ex - vivo frequency of Mtb specific T cells was calculated
per time point, per person, as the average number of spot forming
units (SFU) for wells containing antigen and compared with the
average SFU in the control wells. To account for well-to-well
variance among technical replicates, a standard deviation of the
media control was calculated. A positive ELISPOT assay was
defined as one in which the Mtb specific T cell response was at
least two standard deviations above the background control. If
these criteria were met, the mean of the background was
subtracted out to enumerate the Mtb specific T cell response per
250,000 T cells. A positive PHA response was defined as
$100 SFU per well.
To assess the overall change in the Mtb specific CD4+ and
CD8+ T cell response over 24 weeks across 3 time points during
antituberculosis treatment, a negative binomial mixed model for
over-dispersed spot forming counts was used, with significance at
0.05. A negative binomial model was chosen and is appropriate for
(1) ELISPOT count data (as opposed to continuous data), and (2)
correlations within subjects when using repeated measures study
design. Goodness of fit tests were performed to check model
specifications and potential overdispersion or underdispersion in
the Poisson regression. The generalized estimating equation (GEE)
approach was adopted to estimate standard errors for the
correlated data and the quasi-likelihood under the independent
model criteria (QIC) for GEE was used to define optimal
covariance structure. [28]. The significance level (p value) for
pairwise comparisons between time points (0–8 weeks, 0–24 weeks)
were reported after adjustment for multiple comparisons using the
Bonferroni method. The percent decrease over 24 weeks and from
baseline to 8 weeks was calculated from L’Beta estimate for
pairwise comparisons using the following formula (1 – eb). The
overall change in the T cell response to PHA was performed using
the negative binomial mixed model as described above. A
univariate negative binomial model was used to assess the effect
of BMI (categorical variable #17 as reference), gender (female as
reference), age (continuous variable), AFB smear grade (0–4), and
quantitative mycobacterial cultures (colony forming units (CFU))
on the Mtb specific T cell response at the baseline time point., If a
p value was #0.1, the variable was included in the multivariate
model with the principal variable of interest, treatment duration.
To analyze the change in microbiologic burden among subjects at
baseline and week 4, as measured by the log of colony forming
units, the nonparametric Wilcoxon signed rank test was used.
Statistical analysis was performed in SAS version 9.2 (SAS
Institute Inc., Cary, North Carolina, USA) and graphing was
performed in Statistica (StatSoft, Tulsa, Oklahoma, USA).
Results
Characterization of TB patient cohort
Fifty-one, HIV-negative subjects with pulmonary TB were
invited to participate in the study and baseline characteristics were
collected from 50 subjects. The mean age of the clinical cohort was
26.666.0 years (Table 1). Twenty-four percent (12/50) were
female. The average BMI was 18.863.1. Fifteen (30%) were
malnourished as defined by a BMI#17 [24]. All subjects had AFB
smear-positive, culture confirmed pulmonary TB. Eight subjects
had pulmonary and extrapulmonary TB, including 5 with pleural
involvement. For the sites of extra-pulmonary disease, 5 had
pleural disease, 1 had mediastinal involvement, and 2 had
disseminated disease. Over one-third reported fevers, night sweats
and loss of appetite. Nausea, dizziness, joint pain, headache,
vomiting, diarrhea, and numbness were less commonly reported
(2–8%; data not shown). Ninety-eight percent of enrolled subjects
had cavitation on initial CXR. The one individual without
cavitation did not have blood drawn beyond baseline. Extensive
radiographic involvement, greater than K of the thoracic cavity,
was noted in 31 (62%) subjects. Over one-half of the subjects had a
sputum smear grade of 4+ at entry. Two subjects were later
determined to have drug resistant TB on initial susceptibility
testing; one subject was resistant to isoniazid and rifampin and
other was resistant to isoniazid only. Treatment of these two
patients was modified according to National Tuberculosis
Program guidelines. The data were analyzed with and without
inclusion of these two subjects, and there was no difference in the
results. Thus, these subjects were retained in the final analysis.
One subject with drug susceptible pulmonary TB died of unknown
causes. All subjects improved during the treatment interval by
standard microbiologic measures (Table 2).
Immune response to Phytohemeagglutinin (PHA)
improves during treatment
Blood was drawn at baseline, week 8 and week 24 of treatment
for 49, 48, and 42 subjects respectively and interpretable
ELISPOT results were available from all subjects. Ten subjects
did not have blood drawn for at least one of the three time points
for ELISPOT analysis, and 3 of the 10 subjects were missing blood
from the week 8 and week 24 time points. The median mitogen or
PHA responses (SFU) for the CD4 and CD8 ELISPOT were 204
(interquartile range of 144–373) and 193 (interquartile range 91 –
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336) respectively at baseline. Using the same approach to assess
the Mtb specific T cell responses during treatment as described in
the methods, the response to PHA increased significantly with
duration of treatment for both the CD4+ and CD8+ T cells. For
the CD4+ T cells, the average response (SFU) to PHA at baseline,
week 8 and week 24 was 248, 298, and 323 respectively with a
significant difference during treatment (p = 0.038). For the CD8+ T
cells, the average response (SFU) to PHA at baseline, week 8 and
week 24 was 211, 259, and 283 respectively, also demonstrating a
significant difference during treatment (p = 0.005). All but 3
individuals had a detectable Mtb specific T cell response, greater
than two standard deviations above the media at baseline.
Table 1. Baseline Characteristics.
Characteristics
Clinical
Females, n (%) 12 (24)
Mean age (years 6 standard deviation) 26.666.0
Body mass index at baseline (kg/m2 6 standard deviation) 18.863.1
Fever n (%) 18 (36)
Night sweats n (%) 24 (48)
Anorexia n (%) 19 (38)




Single or multiple, diameter ,4 cm in aggregate 18 (36)
Single or multiple, diameter $4 cm in aggregate 31 (62)
Extent
Limited, lesions ,1/4 of thoracic cavity 0 (0)
Moderate, lesions ,K of thoracic cavity 19 (38)
Extensive, lesions involving .K of thoracic cavity 31 (62)
Pleural disease 5 (10)
Total n (%) 50 (100)
doi:10.1371/journal.pone.0081564.t001
Table 2. Microbiologic burden of mycobacterium tuberculosis in relation to duration of treatment.
Diagnostic Test Time Point
AFB smear grade n (%) Baseline – Week 0 Week 8 Week 24
4+ 29 (58) 0 (0) 0 (0)
3+ 14 (28) 6 (12.2) 0 (0)
2+ 5 (10) 7 (14.3) 0 (0)
1+ 2 (4) 8 (16.3) 3 (7)
Negative 0 (0) 28 (57.2) 40 (93)
Missing data n 0 1 7
Mycobacterial growth on 7H10 solid media n (%)
.200 col. 50 (100) 0 (0) 0 (0)
20–100 col. 0 (0) 3 (6.1) 0 (0)
,20 col. 0 (0) 10 (20.4) 0 (0)
No growth 0 (0) 36 (73.5) 40 (100)
Contamination 0 0 5
Missing data n 0 1 5
Total n (%) * 50 (100) 49 (100) 40 (100)
Definition of abbreviations: col. = colonies
*Total n (%) calculated less missing data and contamination
doi:10.1371/journal.pone.0081564.t002
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Mtb specific CD8+ T Cells Decline with Antituberculosis
Treatment
We hypothesized that the frequency of Mtb specific CD8+ T
cells could be used as a surrogate marker of response to therapy
and would decrease during effective antituberculosis treatment. To
test this hypothesis, we analyzed the Mtb specific CD4+ and CD8+
T cell response by IFN-c ELISPOT in response to ESAT-6 and
CFP-10 during antituberculosis treatment. Using a negative
binomial mixed model, we first evaluated the overall change in
the Mtb specific CD4+ and CD8+ T cell response over 24 weeks of
antituberculosis treatment, independent of other variables. Taking
into account all available time points (n = 3), there was a significant
difference in the Mtb specific CD8+ T cell response during the 24
weeks of treatment (p,0.0001; Figure 1). Conversely, the Mtb
specific CD4+ T cell response did not demonstrate a significant
difference over 24 weeks of antituberculosis treatment. Individual
profiles of the absolute change in the Mtb specific T cell responses
from baseline to week 8 and baseline to week 24 are shown in
Figure 2 and show the magnitude and direction of the changes in
T cell responses between the time points.
The effect of malnutrition on the Mtb specific T cell
response during antituberculosis treatment
To explain this difference between the Mtb specific CD4+ and
CD8+ T cell responses over the 24 weeks of treatment, we
postulated that nutritional status could be differentially affecting
Mtb specific CD4+ and CD8+ T cell responses. As a secondary
analysis, we sought to determine whether an association between
the Mtb specific CD4+ or CD8+ T response, if associated with time
on treatment, might be correlated with malnutrition. In this
regard, protein calorie malnutrition has been associated with
reduced lymphocyte replication as well as a lower IFN-c response
in animal models [29,30]. Furthermore, in a prior study looking at
a HIV-negative cohort undergoing antituberculosis treatment,
depressed IFN-c in response to purified protein derivative was
observed over a 12 month observation period [31]. To explore if
the Mtb specific T cell response was affected by malnutrition, we
used the BMI as a biomarker. Forty-eight subjects had both
ELISPOT and BMI data for analysis at baseline. The Mtb specific
CD4+ T cell response at baseline was significantly reduced in
subjects with moderate to severe malnutrition (BMI#17; n = 14)
compared with subjects with a BMI.17 (n = 34; p = 0.0067). The
Mtb specific CD8+ T cell response was less affected by baseline
BMI (Table 3 and Figure 3). We postulated that during treatment,
as BMI improved, the Mtb specific T cell response would improve.
Eleven of the original 14 subjects with a baseline BMI#17 had
longitudinal data (Figure 4). In the subgroup of subjects that began
antituberculosis treatment with a low BMI, no clear pattern
emerges for the Mtb specific CD4+ T cell response, however, the
Mtb specific CD8+ T cell response appears to decline for several
subjects, as seen in the full cohort (Figure 4). We evaluated other
covariates to assess the impact on the Mtb specific T cell response,
including sex, age, baseline AFB smear grade, cavitary disease,
and radiographic extent of disease. These covariates did not alter
the Mtb specific T cell response thus were not included in the
multivariate analysis.
To explore the association of malnutrition with the Mtb specific
T cell response and treatment duration, we developed a
multivariate model. Using a negative binomial mixed model, we
evaluated the overall change in the Mtb specific CD4+ and CD8+
T cell response over 24 weeks of antituberculosis treatment, using
BMI as a biomarker for nutritional status. Taking into account all
available time points (n = 3), and BMI, the Mtb specific CD4+ T
cell response was not significantly associated with treatment
duration in the multivariate analysis (Table 3). In a parallel
multivariate analysis, we analyzed the Mtb specific CD8+ T cell
response adjusted for BMI. There was a significant difference in
the Mtb specific CD8+ T cell response during the 24 week
treatment interval (p,0.0001; Table 3). Furthermore, in a pairwise
analysis, there was a significant difference from baseline to 8 weeks
(p = 0.023) and from baseline to 24 weeks (p = 0.0003). The
estimated Mtb specific CD8+ T cell response decreased by 58.4%
at 24 weeks, with the majority of the decrease (38.7%) observed at
8 weeks.
Figure 1. Magnitude of Mycobacterium tuberculosis (Mtb) specific T cell responses in smear and culture positive, HIV negative,
pulmonary TB patients over time during antituberculosis therapy. The magnitude of the Mtb specific CD4+ T cell response (A) and Mtb
specific CD8+ T cell response (B) is shown by IFN-c ELISPOT in response to ESAT-6 and CFP-10 and reported in spot forming units per 250,000 T cells.
Evaluable samples (n) analyzed per time point were 49, 48 and 42 for baseline, week 8 and week 24 respectively. A negative binomial mixed model
was used to assess the overall change during 24 weeks. Raw data, surrounded by the box demonstrates the distribution of 25–75% of the data, with
the whiskers representing the non-outlier data, and the horizontal line depicting the median. Raw data is shown with a triangle, outliers with a circle,
and extremes with a star.
doi:10.1371/journal.pone.0081564.g001
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Neither smear grade nor quantitative cultures were
We postulated that the Mtb specific CD8+ T cell response
would be associated with other surrogates of bacterial burden such
as AFB smear grade, delayed clearance of Mtb from sputum, or
persistent culture positivity. However, baseline AFB smear grade
was not associated with the magnitude of Mtb specific CD4+ or
CD8+ T cell responses. Given the relative imprecision of the AFB
smear grade, we sought to determine if quantitative mycobacterial
cultures (CFU) were associated with Mtb specific CD4+ or CD8+
T cell responses. Of the 50 subjects with baseline and follow up
microbiologic data, 35 (70%) had quantitative mycobacterial
cultures performed at baseline and 14 (28%) again at week 4.
Given the paucity of data at 4 weeks and lack of matching blood
draw at that time, only the baseline data were analyzed. Using a
negative binomial model, we found that baseline quantitative
mycobacterial cultures of sputum were not correlated with the
magnitude of the Mtb specific CD4+ or CD8+ T cell response
(data not shown). We also postulated that subjects with delayed
mycobacterial clearance or treatment failure would have persis-
tently elevated Mtb specific CD8+ T cell responses. However, as
shown in Table 2, over one-half (57%) were smear negative and
three-quarters (73.5%) were culture negative at 8 weeks. Further-
more, subjects had a dramatic decline by several logs in
quantitative cultures by week 4 (Figure 5; p = 0.0005). For the
subset that required 9 months of therapy due to AFB positive
sputum at 8 weeks (n = 21), follow up cultures at nine months
remained negative (data not shown). As a result, we were unable to
establish a direct correlation between microbiologic measures of
bacterial burden and the Mtb specific T cell response.
Discussion
We have demonstrated that the estimated Mtb specific CD8+ T
cell response decreased by 58.4% at 24 weeks, with the majority of
the decrease noted (38.7%) at 8 weeks in subjects receiving
Figure 2. Individual profiles of the absolute change in the Mtb specific T cell responses (spot forming units; SFU) from baseline to
week 8 and baseline to week 24 in smear and culture positive, HIV negative, pulmonary TB patients during antituberculosis
therapy. The waterfall plots show the absolute change in magnitude (SFU) between the baseline time point to week 8 for the Mtb specific CD4+ (A)
and CD8+ (C) T cell response. The absolute change in magnitude for the baseline time point to week 24 is shown for the Mtb specific CD4+ (B) and
CD8+ (D) T cell response. Black bars represent SFU decreasing from baseline to the respective time point, whereas white bars represent increasing
SFU from baseline to the respective time point.
doi:10.1371/journal.pone.0081564.g002
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associated with Mtb specific T cell responses
successful antituberculosis treatment. Surrogates of bacterial
burden and response to therapy for Mtb infection have enormous
potential in clinical practice to improve the management of those
exposed to the Mtb, and those with TB disease. Among those who
have been infected, but do not have TB disease, such markers
might serve to reflect bacterial eradication, containment, growth
or new exogenous infection. In this regard, such a marker might
facilitate the identification of those who will progress to TB or,
among subjects with TB disease, provide early identification of
individuals at risk for treatment failure or relapse after treatment.
Because CD8+ T cells recognize antigen derived from the
intracellular environment, it is biologically plausible that they
may discern a gradient of infection and distinguish infection from
exposure. In this regard, the Mtb specific CD8 response in animal
models correlates with bacterial load as demonstrated by the
correlation with in vivo growth of Mtb [16] and computed
tomography and patho-histologic findings [17]. In addition, in a
murine model of Mtb treatment, a reduction in the frequency of
Mtb specific CD8+ T cells, with a shift toward a central memory
phenotype, has been demonstrated [18]. Additionally, Mtb specific
CD8+ T cells preferentially recognize cells heavily infected with
Mtb [15] and the presence of a robust Mtb specific CD8+ T cell
response discerns young children with TB from their healthy, age
matched controls with extensive environmental exposure [19].
Thus, we hypothesized that the CD8+ T cell response by virtue of
sensing intracellular mycobacterial antigen may be a surrogate
marker of response to therapy, and should decline with
appropriate antituberculosis treatment.
To our knowledge, this is the first study in humans to
prospectively evaluate changes in the Mtb specific CD8+ T cell
response from the peripheral blood during TB treatment. We
demonstrate a significant difference in the Mtb specific CD8+ T
cell response during antituberculosis treatment, with a decline of
58% at 24 weeks. Interestingly, the majority of the overall decline,
nearly 39%, occurred within 8 weeks and was relatively unaffected
by malnutrition. In contrast, we found that the Mtb specific CD4+
T cell response exhibited substantial variability. In a parallel
multivariate analysis, the Mtb specific CD4+ T cell response
showed a marginal difference over 24 weeks (p = 0.07), with the
major effect demonstrated in a pairwise comparison at 0 and 24
weeks (p = 0.08). This degree of variability and the marginal
decrease is consistent with previously published studies evaluating
commercial IGRAs, which are based on the CD4+ response,
during antituberculosis treatment[9,10,12,13].
Our finding that there is an early decline in the Mtb specific
CD8+ response during the initial phase of successful TB treatment
suggests that the Mtb specific CD8+ T cell response, potentially by
detecting intracellular bacterial burden, may be a more accurate,
and direct surrogate of response to therapy than the CD4+
response. Alternatively, it is possible that the Mtb specific CD4+ T
cell response is more confounded by other host factors such as
malnutrition, although our results do not support malnutrition as
the sole explanation for the poor association between the Mtb
specific CD4+ T cell response and duration of treatment over 24
weeks of antituberculosis therapy. The effects of malnutrition on
immune dysregulation are well known [32] and lack of weight gain
specifically in patients with TB has been associated with negative
clinical outcomes such as relapse [33]. Specifically, protein calorie
malnutrition is associated with lymphopenia as well as anergy to
PPD in animal models [34]. Further, in subjects presenting with
TB, diminished IFN-c production in response to Mtb antigens has
been observed, a defect that persisted for as long as a year
following the initiation of TB treatment [31]. While the study by
Hirsch et al. did not delineate CD4+ versus CD8+ T cell responses,
the cohort was similar to the one presented herein in that patients
presented with advanced disease, and were likely malnourished.
Interestingly, we were able to follow the Mtb specific T cell
responses of 11 malnourished subjects (BMI#17) and show that
some subjects were able to reconstitute their CD4+ T cell
responses by the end of treatment. Conversely, for many of the
subjects, the Mtb specific CD8+ T cell response declined, as seen
with subjects with a normal BMI. Although we demonstrate a
differential effect of malnutrition on the CD4+ T cell response, we
suspect that severe protein calorie malnutrition affects both the
CD4+ and CD8+ T cell response and we were underpowered to
fully assess the effect of malnutrition on the CD8+ T cell response.
Additionally, the use of BMI as a surrogate for malnutrition may
be enhanced in future studies by different measures of nutritional
status, especially in women [35].
Table 3. Univariate and multivariate analyses of predictors of the Mtb specific T cell response among HIV negative, smear positive,
culture confirmed pulmonary TB patients undergoing antituberculosis treatment.
CD4+ T Cell Response (p value) CD8+ T Cell Response (p value)
Predictor Variable Univariate Multivariate ` Univariate Multivariate `
Treatment duration (weeks) 0.0582 ` 0.0699 ,0.0001 ` ,0.0001
BMI * (ref#17) 0.0067 { 0.0136 0.9286 { 0.4995
Gender (ref: female) 0.4271 { n/a 0.8982 { n/a
Age 0.1204 { n/a 0.3667 { n/a
AFB smear grade1 (ref: smear neg) 0.2975 { n/a 0.2378 { n/a
Extent || (ref: limited to moderate) 0.9007 { n/a 0.3539 { n/a
Cavitation ** (ref: #4 cm) 0.8037 { n/a 0.7226 { n/a
*BMI is included in the multivariate model with treatment duration.
{The association between variables and the Mtb specific T cell response was analyzed at the baseline time point.
`Statistical method: a negative binomial mixed model.
1AFB smear grade 0 (smear negative) to 4+.
||
Extent: limited or moderate versus extensive by chest radiograph.
**Cavitation: # 4 cm versus .4 cm.
n/a. not applicable.
doi:10.1371/journal.pone.0081564.t003
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In the mouse model, removal of antigen leads T cells to
transition from cytokine producing effector T cells to those without
short-term effector capacity [36]. Consequently, it has been
postulated that the commercial IGRAs might be useful in
monitoring TB treatment [4]. In this regard, many studies have
shown modest declines in IFN-c release using either non-
commercial [6,37] or the commercial IGRAs [7,9,10,12,13].
However, the quantitative variability of these responses both
within and between individuals is striking. We propose that the
variability seen across studies is associated with the use of
peripheral blood mononuclear cells, which are dominated by
CD4+ T cells. Thus, as CD4+ T cells recognize antigen sampled
from either the intracellular or extracellular milieu, a specific
CD4+ T cell response may be secondary to prior antigen-
sensitization by Mtb rather than ongoing, intracellular infection.
Our study demonstrating persistence of Mtb specific CD4+ T cell
responses until week 24 of therapy is concordant with prior reports
suggesting that Mtb antigens or the response to these antigens may
persist for long periods following treatment [38]. Regardless, our
finding that the Mtb specific CD4+ T cell response was impacted
by malnutrition may account for performance differences in
IGRAs when used in low resource/high incidence versus high
resource/low incidence settings.
Our study has several unsettled points that need further study.
Neither AFB smear grade, nor quantitative cultures were
associated with the frequency of Mtb specific CD8+ T cell
Figure 3. Mycobacterium tuberculosis (Mtb) specific T cell responses at baseline and BMI. The magnitude of the Mtb specific T cell response
by IFN-c ELISPOT to ESAT-6 and CFP-10, and reported in spot forming units/250,000 T cells, is shown at baseline for the Mtb specific CD4+ response
(A) and the Mtb specific CD8+ response (B) for BMI#17 (n = 14) and .17 (n = 34). A negative binomial model was used to assess differences in the
Mtb specific T cell responses and BMI#17 and .17. Raw data, shown as a triangle, surrounded by the box demonstrates the distribution of 25–75%
of the data, with the whiskers representing the non-outlier data, and the horizontal line depicting the median.
doi:10.1371/journal.pone.0081564.g003
Figure 4. Mycobacterium tuberculosis (Mtb) specific T cell responses during antituberculosis treatment in subjects with baseline
malnutrition (BMI#17). The subgroup of subjects, who started therapy with a BMI#17 with baseline and week 24 analyzable ELISPOT data (n = 11)
are shown. The magnitude of the Mtb specific T cell response is shown by IFN-c ELISPOT to ESAT-6 and CFP-10 and reported in spot forming units per
250,000 T cells. Connected lines at baseline and week 24 reflect a individual subject’s profile for the Mtb specific CD4+ T cell response (A) and the Mtb
specific CD8+ T cell response (B).
doi:10.1371/journal.pone.0081564.g004
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responses. From these data, as well as the observation of high
frequency CD8+ T cell responses in those with LTBI [39] we
would suggest that there is not a linear relationship between the
magnitude of the Mtb specific CD8+ T cell response and
traditional markers of bacterial burden such as smear positivity,
chest radiographs and quantitative cultures. We postulate that
each individual has a CD8 ‘‘set point’’ which reflects the complex
interplay of antigenic exposure, in conjunction with host factors
such as the HLA background. Nonetheless, our findings are
concordant with the observation that removal of antigen results in
decreasing T cell frequencies, and help explain the observed
reduction in CD8+ T cell frequency as a result of antituberculosis
therapy. Further, because our clinical cohort improved on
appropriate antituberculosis treatment, we were unable to evaluate
subjects failing therapy. As a result, it remains to be determined
whether or not monitoring of the Mtb specific CD8+ T cell
response will be of use for the prediction of treatment failure or
relapse following treatment. For instance, people with unrecog-
nized drug resistance would be expected to have delayed microbial
clearance, which might result in a persistently elevated CD8+ T
cell response. In this regard, our study enrolled two subjects with
drug resistance, both of whom were changed to appropriate
therapy early during their treatment course and demonstrated
good clinical, and microbiologic response. As discussed, an
analysis with and without the inclusion of these subjects was
performed, and there was no change in our results. Thus, we
believe that these subjects also had a decrease in bacterial burden,
having been switched early to appropriate therapy. Thus, we were
unable to determine if monitoring the Mtb specific CD8 response
would identify subjects with drug resistance with the current
cohort.
A further limitation was the use of ESAT-6 and CFP-10 in
conjunction with IFN-c as the immunological endpoint. In this
regard, identification of novel Mtb antigens that are either disease
[40] or T cell specific might improve the specificity and sensitivity
of the immune assessment of bacterial burden (Lewinsohn
unpublished data). Similarly, a more sophisticated measurement
of T cell phenotype and function could provide additional insight
into antigenic persistence, and hence provide additional clinical
utility. This potential is illustrated by the recent findings that T cell
production of IL-2 is associated with bacterial clearance [41,42].
In summary, we have demonstrated that the estimated Mtb
specific CD8+ T cell response decreased by 58.4% at 24 weeks,
with the majority of the decrease noted (38.7%) at 8 weeks in
subjects receiving successful antituberculosis treatment. Our data
support the hypothesis that the frequency of Mtb specific CD8+ T
cells, potentially as consequence of decreasing intracellular
mycobacterial antigens, declines with antituberculosis therapy
and may prove to be a surrogate marker of response to therapy. In
contrast, the association of the Mtb specific CD4+ response with
treatment was marginal, and affected by underlying malnutrition.
At present, additional research is needed into the Mtb specific
CD8+ T cell response during treatment at earlier time points (prior
to 8 weeks), in subjects who fail treatment, and in subjects with
HIV/TB coinfection. Such research would help to evaluate the
practical application of the frequency of Mtb specific CD8+ T cells
as a reliable and useful surrogate marker of response to therapy
that may be used alone or in combination with other immune
surrogates of antigen load [43,44].
Figure 5. Quantitative cultures and treatment duration. Quantitative cultures from subjects with smear positive pulmonary TB as shown by
the log of colony forming units (CFU) enumerated on 7H10 media at week 0 (n = 35) and week 4 (n = 14). Raw data, shown as a triangle, surrounded
by the box demonstrates the distribution of 25–75% of the data, with the whiskers representing the non-outlier data, and the horizontal line
depicting the median. The dotted line connects the median points. Wilcoxon signed rank test was performed comparing subjects with week 0 and
week 4 (n = 12).
doi:10.1371/journal.pone.0081564.g005
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